These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32198729)

  • 1. In silico analyses of the tumor microenvironment highlight tumoral inflammation, a Th2 cytokine shift and a mesenchymal stem cell-like phenotype in advanced in basal cell carcinomas.
    Lefrançois P; Xie P; Gunn S; Gantchev J; Villarreal AM; Sasseville D; Litvinov IV
    J Cell Commun Signal; 2020 Jun; 14(2):245-254. PubMed ID: 32198729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Basal Cell Carcinoma (BCC) Tumour Microenvironment to Other Solid Malignancies.
    Zhang ER; Ghezelbash S; Xie P; Fotovati M; Litvinov IV; Lefrançois P
    Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
    Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local immune response in cutaneous basal cell carcinoma.
    Omland SH
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment.
    Kaporis HG; Guttman-Yassky E; Lowes MA; Haider AS; Fuentes-Duculan J; Darabi K; Whynot-Ertelt J; Khatcherian A; Cardinale I; Novitskaya I; Krueger JG; Carucci JA
    J Invest Dermatol; 2007 Oct; 127(10):2391-8. PubMed ID: 17508019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
    Yurchenko AA; Pop OT; Ighilahriz M; Padioleau I; Rajabi F; Sharpe HJ; Poulalhon N; Dreno B; Khammari A; Delord M; Alberti A; Soufir N; Battistella M; Mourah S; Bouquet F; Savina A; Besse A; Mendez-Lopez M; Grange F; Monestier S; Mortier L; Meyer N; Dutriaux C; Robert C; Saiag P; Herms F; Lambert J; de Sauvage FJ; Dumaz N; Flatz L; Basset-Seguin N; Nikolaev SI
    Clin Cancer Res; 2022 Apr; 28(7):1422-1432. PubMed ID: 35078858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
    Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
    J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Efficacy of Vismodegib After its Withdrawal and Patients' Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI).
    Villani A; Megna M; Fabbrocini G; Cappello M; Luciano MA; Costa C; Scalvenzi M
    Dermatol Ther (Heidelb); 2019 Dec; 9(4):719-724. PubMed ID: 31506916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS.
    Kaatz M; Mohr P; Livingstone E; Weichenthal M; Kreuter A; Pföhler C; Leiter U; Ulrich J; Utikal JS; Gutzmer R; Herbst R; Schadendorf D
    Acta Derm Venereol; 2022 Apr; 102():adv00695. PubMed ID: 35199180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transcriptional landscape analysis of basal cell carcinomas reveals novel signalling pathways and actionable targets.
    Litvinov IV; Xie P; Gunn S; Sasseville D; Lefrançois P
    Life Sci Alliance; 2021 Jul; 4(7):. PubMed ID: 33972406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p16 Protein in Cutaneous Basal Cell Carcinoma: Still far from Being Clearly Understood.
    Bartoš V
    Acta Dermatovenerol Croat; 2020 Jul; 28(1):43-44. PubMed ID: 32650852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas.
    Boaventura P; Pereira D; Mendes A; Batista R; da Silva AF; Guimarães I; Honavar M; Teixeira-Gomes J; Lopes JM; Máximo V; Soares P
    J Dermatol Sci; 2014 Jan; 73(1):31-9. PubMed ID: 24091058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
    Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I
    JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.
    Peris K; Fargnoli MC; Garbe C; Kaufmann R; Bastholt L; Seguin NB; Bataille V; Marmol VD; Dummer R; Harwood CA; Hauschild A; Höller C; Haedersdal M; Malvehy J; Middleton MR; Morton CA; Nagore E; Stratigos AJ; Szeimies RM; Tagliaferri L; Trakatelli M; Zalaudek I; Eggermont A; Grob JJ;
    Eur J Cancer; 2019 Sep; 118():10-34. PubMed ID: 31288208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology.
    Juhasz ML; Marmur ES
    J Drugs Dermatol; 2014 Jun; 13(6):729-33. PubMed ID: 24918565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sonidegib for the Treatment of Advanced Basal Cell Carcinoma.
    Brancaccio G; Pea F; Moscarella E; Argenziano G
    Front Oncol; 2020; 10():582866. PubMed ID: 33194718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.